Disease · MONDO_0006769
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Relamorelin 10 μg vs Placebo: deaths from any cause | 0 of 169 | 0 of 167 | 336 | NCT03285308 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Meaningful Trends for Vital Signs | 0 of 163 | 0 of 163 | 326 | NCT03285308 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | 70 of 163 | 68 of 163 | 326 | NCT03285308 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results | 3 of 163 | 4 of 163 | 326 | NCT03285308 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: serious adverse events | 16 of 163 | 15 of 163 | 326 | NCT03285308 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: deaths from any cause | 0 of 156 | 0 of 155 | 311 | NCT03426345 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Meaningful Trends for Vital Signs | 0 of 155 | 0 of 152 | 307 | NCT03426345 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | 86 of 155 | 75 of 152 | 307 | NCT03426345 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results | 2 of 155 | 1 of 152 | 307 | NCT03426345 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: serious adverse events | 8 of 155 | 6 of 152 | 307 | NCT03426345 | Trial comparisons |
| Relamorelin 10 μg vs Placebo: Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c) | 111 of 151 | 80 of 146 | 297 | NCT03426345 | Trial comparisons |
| 10 mg Metoclopramide Nasal Spray vs Placebo Nasal Spray: deaths from any cause | 0 of 102 | 0 of 103 | 205 | NCT02025725 | Trial comparisons |
| 10 mg Metoclopramide Nasal Spray vs Placebo Nasal Spray: serious adverse events | 3 of 102 | 2 of 103 | 205 | NCT02025725 | Trial comparisons |
| Nortriptyline vs Placebo: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits | 15 of 65 | 14 of 65 | 130 | NCT00765895 | Trial comparisons |
| Nortriptyline vs Placebo: serious adverse events | 5 of 65 | 1 of 65 | 130 | NCT00765895 | Trial comparisons |
| CAMICINAL 25 MG vs PLACEBO: deaths from any cause | 0 of 58 | 0 of 56 | 114 | NCT02210000 | Trial comparisons |
| CAMICINAL 25 MG vs PLACEBO: serious adverse events | 3 of 58 | 2 of 56 | 114 | NCT02210000 | Trial comparisons |
| Buspirone vs Placebo: deaths from any cause | 0 of 47 | 0 of 49 | 96 | NCT03587142 | Trial comparisons |
| Buspirone vs Placebo: serious adverse events | 1 of 47 | 1 of 49 | 96 | NCT03587142 | Trial comparisons |
| Metoclopramide Nasal Spray vs Placebo Nasal Spray: deaths from any cause | 0 of 26 | 0 of 27 | 53 | NCT02025751 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006769/comparisons